What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

A middle school student curious about science grows into a college-bound scientist.

Compound offers a potential tool for fighting drug-resistant malaria parasites.

New Global Head of Ophthalmology Research sees the eye as a frontier of biomedical research.

Umbilical cords are a potentially life-saving source of blood stem cells for people with leukemia and other diseases. But there aren’t enough cells to meet demand. Now an experimental treatment offers hope for a solution.

Researchers discover that networks of proteins circulating in the blood influence the development and progression of chronic diseases.